<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499445</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1160004</org_study_id>
    <nct_id>NCT02499445</nct_id>
  </id_info>
  <brief_title>Myocardial Injury in Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimens in OPCAB Surgery</brief_title>
  <official_title>Comparisons of Myocardial Injury After Using Different Anesthetics Regimens for Off-pump Coronary Artery Bypass Surgery: Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients undergoing off-pump coronary artery bypass (OPCAB) surgery with different
      anesthesia regimens: remifentanil (0.75 mcg/kg/min) and propofol (TCI effect-site
      concentration 0.8-1.5 mcg/ml) (Group -RP); remifentanil (0.75 mcg/kg/min) and sevoflurane
      (end-tidal 0.8 vol%) (Group-RS), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI
      effect site concentration 0.35-0.75 ng/ml) (Group-SS), intergroup difference in the level of
      Troponin I (c-TnI) and creatinine kinase subtype-MB is determined before surgery (control),
      during vascular graft harvesting (harvesting), after completing graft construction
      (postgrafting), and one day after surgery (postoperative).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the difference of myocardial injury upon using different anesthesia regimens:
      remifentanil-based regimen versus sevoflurane-sufentanil balanced regimen.

      Patients undergoing off-pump coronary artery bypass (OPCAB) surgery are randomly allocated to
      get remifentanil (0.75 mcg/kg/min) and propofol (TCI effect-site concentration 0.8-1.5
      mcg/ml) (Group -RP), remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%)
      (Group-RS), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site
      concentration0.35-0.75 ng/ml) (Group-SS).

      Intergroup difference in the level of Troponin I (c-TnI) and creatine kinase-MB is determined
      before surgery (control), during vascular graft harvesting (harvesting), after completing
      graft construction (postgrafting), 1 day after surgery (postoperative).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>troponin I</measure>
    <time_frame>one day after surgery</time_frame>
    <description>troponin I for myocardial injury</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>creatinin kinase-MB</measure>
    <time_frame>one day after surgery</time_frame>
    <description>creatinine kinase-MB</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Remifentanil and propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil and sevoflurane 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane 2 and sufentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>administering remifentanil for anesthesia maintenance</description>
    <arm_group_label>Remifentanil and propofol</arm_group_label>
    <arm_group_label>remifentanil and sevoflurane 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane 1</intervention_name>
    <description>administering sevoflurane 1 for anesthesia maintenance</description>
    <arm_group_label>remifentanil and sevoflurane 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane 2</intervention_name>
    <description>administering sevoflurane 2 for anesthesia maintenance</description>
    <arm_group_label>sevoflurane 2 and sufentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>administering propofol for anesthesia maintenance</description>
    <arm_group_label>Remifentanil and propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sufentanil</intervention_name>
    <description>administering sufentanil for anesthesia maintenance</description>
    <arm_group_label>sevoflurane 2 and sufentanil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient undergoing OPCAB surgery

          -  patient signed written informed consent

        Exclusion Criteria:

          -  patient with Intra-aortic balloon pump

          -  patient with renal replacement therapy

          -  patient wants to withdraw the participation to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>July 15, 2015</last_update_submitted>
  <last_update_submitted_qc>July 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Tae-Yop Kim, MD PhD</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

